PREVALENCE OF OCULAR SURFACE DISEASE IN GLAUCOMA PATIENTS USING ANTI-GLAUCOMA MEDICATIONS.

Vinutha B V¹, N. V. V. Himamshu², Sundeep³, Niveditha H⁴, Pooja Patil⁵, Liji P⁶, M. S. Smitha Gowda⁷.

1. Senior Resident, Department of Ophthalmology, Kempegowda Institute of Medical Sciences and Research Center.
2. Professor and HOD, Department of Ophthalmology, Kempegowda Institute of Medical Sciences and Research Center.
3. Associate Professor, Department of Ophthalmology, Kempegowda Institute of Medical Sciences and Research Center.
4. Associate Professor, Department of Ophthalmology, Kempegowda Institute of Medical Sciences and Research Center.
5. Post Graduate, Department of Ophthalmology, Kempegowda Institute of Medical Sciences and Research Center.
6. Post Graduate Post Graduate, Department of Ophthalmology, Kempegowda Institute of Medical Sciences and Research Center.

CORRESPONDING AUTHOR
Dr Niveditha H,
# 012, shuddha shelters,
Behind shantiniketan school,
Someshwara layout,
Bilekahalli, Bangalore – 76.
Email- vinutha_seetharam@yahoo.co.in

HOW TO CITE THIS ARTICLE:

ABSTRACT: AIM; To evaluate the prevalence of ocular surface disorder (OSD) in patients using anti-glaucoma medications METHODS; 150 eyes of 75 glaucoma patients on topical anti-glaucoma medication with preservatives were studied. Patients with history of use of topical corticosteroids, cyclosporine, anti-inflammatory drugs or other topical medications within last 3 months were excluded. Patients completed Ocular Surface Disease Index questionnaire, underwent evaluation by Schirmer test, tear breakup time, corneal and conjunctival lissamine green staining. RESULTS; Mean age of patients was 56.5 (range 23 – 80) years. 50 (67%) patients were males and 25 (33%) patients were females.56% patients had primary open angle glaucoma. 41% patients had primary angle glaucoma. 3% patients had ocular hypertension. 44 (59%) patients were on single medication. 25 (33%) patients were on two medications. 6 (8%) patients were on three medications. Mean duration of using medication was 3.8 yrs (range; 5 months – 16 yrs). Duration less than 1yrs -10(13%) patients. 1 to 5 yrs -36(48%) patients. 5 to 1yrs -19(26%) patients. More than 10yrs - 10(13%) patients. 32% patients reported symptoms in at least one eye. Severe symptoms were reported by none. Tear breakup time was abnormal in 54.5% patients, severe abnormality in 20.5% patients. Schirmer testing showed 50.5% patients with decreased tear production in at least one eye, severe tear deficiency in 21.5% patients. Lissamine green staining of conjunctival and cornea showed positive results in 47% patients. None had severe staining. As
duration of treatment and number of medications increased, more patients became symptomatic and test results became abnormal. **CONCLUSION:** High prevalence of ocular surface diseases was noted in patients using anti-glaucoma medications, higher the incidence with increasing number of medications and longer duration of usage. Ocular surface disease must be kept in mind in symptomatic patients as it is likely to affect drug compliance

**KEY WORDS:** anti-glaucoma agents, ocular surface disease, benzalkonium chloride, dry eye

**INTRODUCTION:** Glaucoma is one of the leading causes of blindness in the world today. Majority of glaucoma patients receive topical medical treatment in the form of eye drops. Glaucoma is progressive disease requiring long term treatment often rest of the life. Some of these patients require multiple medications. Anti-glaucoma medications are generally well tolerated. Preservatives are used in these medications to maintain sterility. Long term use of these preserved anti-glaucoma medications is shown to adversely affect conjunctiva and cornea, leading to increased risk of developing or worsening of ocular surface disease¹.

OSD is characterized by inadequate quantity of tear, impairment of protective tear film and ocular surface damage. OSD symptoms include irritation, burning, foreign body sensation, dryness, photophobia, fatigue and fluctuating visual acuity. Several factors such as age, race, sex, associated diabetes mellitus and meibomian gland dysfunction are considered to influence the prevalence of OSD². OSD and glaucoma are both prevalent in elderly, often present as comorbid conditions.

**METHODS:** This is a prospective observational study. 75 patients attending glaucoma clinic of Kempegowda Medical college Ophthalmology department were studied. Patients aged 18 years and above with Primary Open Angle Glaucoma, primary angle closure glaucoma and ocular hypertension were recruited. These patients were being treated with topical anti-glaucoma medications with preservatives. Patients with history of using any other topical medications, YAG laser, any anterior segment pathology or ocular surgery were excluded.

Informed consent was taken from selected patients. Demographic information, brief medical history and information on concomitant medicine use were obtained from patient's medical records. All the eligible patients were asked to complete Ocular Surface Disease Index [OSDI] questionnaire. After completing the OSDI questionnaire, patients under went three standard clinical tests for the detection of ocular surface disorder – Schirmer 1 test, Tear breakup time (TBUT) and Lissamine green staining of conjunctiva and cornea. The OSDI questionnaire was designed as a screening survey to assess symptoms and their impact on vision related function³. The 12 questions of OSDI questionnaire were graded on the scale of 0 to 4. 0 – none of the time, 1 – some of the time, 2 – half of the time, 3 – most of the time, 4 – all the time. The total OSDI score was calculated using the formula

$$
OSDI = \frac{\text{sum of scores for all questions asked}}{25} \times 25 \quad \text{Total number of questions answered}
$$

Using OSDI score, patients were categorized as normal (score 0 – 12), mild OSD symptoms (score 13 – 22), moderate symptoms (score 23 – 32) and severe symptoms (33 – 100).

Schirmer test 1 (without anesthesia) was done using Whatmann no.41 filter paper (5X35 mm). the filter paper strip was folded over at the labeled end and hocked in the lower cul de sac over the junction of outer and middle one third of lower lid while patient is looking slightly upwards. The patients were allowed to blink normally. After 5 minutes, filter paper strip was
removed. Moistened filter paper section from the fold was measured in millimeters immediately. If the filter paper strip was completely wet before the time elapsed, it was removed immediately and the time necessary for this was measured. Schirmer test value above 10mm was considered normal, 6 to 10mm mild to moderate and less than, 5mm severe tear deficiency.

Lissamine green staining of conjunctiva and cornea was done by inserting one drop of lissamine green into lower conjunctival sac. Corneal and conjunctival staining was evaluated using moderate light intensity after 30 seconds but before 2 minute had elapsed after installation. Staining was graded using Oxford Scheme. The severity was graded as 0-1 normal, 2-3 mild to moderate and 4-5 severe.

Tear Break Up Time (TBUT) - 2% sodium fluorescein dye was administered into inferior culde sac. Patient was asked to blink several times so that fluorescein dye distributes itself uniformly. Examination was performed with slit lamp using cobalt blue illumination. Patient was asked to blink and keep open without further blinking. TBUT was measured over the cornea as the time from last blink until the appearance of first black spot in the green yellow fluorescein. TBUT results were graded as more than ≥10seconds – normal, 5 – 9 seconds – mild to moderate, <5seconds – severe.

RESULTS: Seventy five patients (150 eyes) participated and completed all the tests involved in the study. 50 patients (67%) were males and 25 patients(33%) were females, mean age of the patients was 56.9 years (range 22- 88years). 40patients (56%) were diagnosed with primary open angle glaucoma, 30 patients (41%) with primary angle closure glaucoma and 5 patients (3%) with ocular hypertension. Mean duration of using medication was 3.8years (range 5 months to 16 years). 10 patients (13%) were using medication for less than 1 year, 36 patients (48%) between 1 – 5 years, 19 patients (26%) between 5-10 years and 10 patients (13%) more than 10 years. 44 patients (58.6%) were on single medication, 25 patients (33.3%) were on two medications and 6 patients (8%) were on three medications.

Results obtained from OSI questionnaire and three tests are summarized in table 1 and graph1. Based on OSDI questionnaire, 32% patients reported symptoms in at least one eye. Severe symptoms were reported by none. Tear breakup time was abnormal in 54.5% patients, severe abnormality in 20.5% patients. Schirmer test showed patients 50.5% with mild to moderate decrease in tear film production in at least one eye, severe tear deficiency in patients21.5%.Lissamine green staining of conjunctiva and cornea showed mild to moderate staining in patients 46.5%, none having severe staining.

Table 2 and graphs 2A, 2B, 2C, 2D shows relationship between OSDI and three test results with respect to duration of treatment. In patients using topical medication less than one year, none of the patients were symptomatic. As the duration of treatment increased, more patients became symptomatic, with 66% showing mild to moderate symptoms. Schirmer test results also showed that in patients using treatment less than one year, 60% had normal, 30% mild to moderate decrease in tear film production in at least one eye and severe tear deficiency in 10% patients. In patients using treatment more than 10 years, only 20% had normal tear production, 60% mild to moderate decrease in tear film production and 20% severe tear deficiency. TBUT value was normal in 40%, mild – moderate in 40% and severe in 20% in patients using treatment less than one year. Patients using treatment more than ten years, TBUT was normal only in 7%, mild –
moderate in 80%. Lissamine green staining of conjunctiva and cornea was normal in 90% and 10% showed mild to moderate staining in patients using medication less than one year. Whereas in patients using medication more than ten years, only 20% showed normal staining and 80% mild to moderate staining.

Table 3 shows OSDI score and test results with respect to number of medications used. As the number of medications increased, OSDI score and test results became more abnormal.

**DISCUSSION:** Ocular surface disease and glaucoma are both prevalent in old age. OSD prevalence increases with age, affecting approximately 11% in 40-59 age group and 18% in older than 80 years in general population⁴.⁵. Prevalence of primary open angle glaucoma increases with age, affecting approximately 1% in 40-49 age group and 8% in older than 80 years⁶. The German Glaucoma and Dry Eye Register showed that incidence of dry eye increases with age, more in women, prevalence increases because of long term use of multiple anti-glaucoma medications⁷.

Robert D Fuechtner et al study reported that 48.4% patients had OSD symptoms, 21.3% mild, 13.3% moderate and 13.8% severe OSD scores⁷.

Leung et al in their study reported 59% patients had symptoms of dry eye and severe symptoms in 27%. They also noted that use of more benzalkonium chloride containing eye drop was significantly associated with higher prevalence of abnormal results on lissamine green stain⁹.

In our study, OSD index score was less compared to other studies, none having severe symptoms. In our study Schirmer test, T-BUT values and lissamine green staining correlated with these studies.

Benzalkonium chloride is most commonly used preservative. it is a quaternary ammonium compound made up of a mixture alkylbenzylidimethylammonium chloride homologues. The concentration of benzalkonium chloride used in ophthalmic eye drops ranges at 0.004% - 0.025%.Evidence from animal and cell line studies has shown that benzalkonium chloride is directly toxic to ocular tissues¹⁰.¹¹. It exerts detergent effect on lipid layer of tear film, reducing its stability causing it to evaporate more rapidly and results in increased ocular dryness¹². Benzalkonium chloride has destructive effect on mucosal glands, decreasing goblet cells and production of protective mucus layer¹³. Benzalkonium chloride causes inflammation of conjunctival layer leading to subconjunctival fibrosis. Subconjunctival fibrosis develops because of increased fibroblastic density in subepithelial substantia propria, linked to an increase in inflammatory cells¹⁴.¹⁵.¹⁶. Immunohistochemical study of conjunctival and trabecular specimens from surgical patients receiving preserved anti-glaucoma treatment revealed significantly greater expression of fibroblastic and inflammatory markers compared with those who did not receive topical treatment¹⁶. Expression of fibroblastic and inflammatory markers was higher in patients receiving multiple drops compared to those using single medication¹⁷. Long term use of topical anti-glaucoma therapy, particularly combination treatment regimes has been associated with failure of glaucoma filtration surgery¹⁶. The toxic effects of preservatives are initially subclinical. Long term cumulative application of preservatives containing anti-glaucoma medications to the ocular surface is associated with development of signs and symptoms of ocular discomfort. Studies have shown that significant higher proportion of patients receiving preserved medications experience discomfort or pain during therapy compared with those treated with preservative free drugs¹⁸.
Our study had a limitation. We did not have control group that could have helped to provide further insight into the relationship between use of eye drops with and without preservatives and OSD.

Conclusion; High prevalence of ocular surface diseases was noted in patients using anti-glaucoma medications, higher the incidence with increasing number of medications and longer duration of usage. Preservative agents have dose dependent toxic effects, compromising tear film stability leading to conjunctival and corneal damage. Patients with side effects are less likely to comply with their treatment and compromising quality of life. Ocular surface disease must be kept in mind in symptomatic patients as it is likely to affect drug compliance.

BIBLIOGRAPHY;


**TABLE 1**

<table>
<thead>
<tr>
<th>Results</th>
<th>OSD (%)</th>
<th>Schirmer (%)</th>
<th>T BUT (%)</th>
<th>Lissamine green (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>68</td>
<td>27</td>
<td>26</td>
<td>53</td>
</tr>
<tr>
<td>Mild-moderate</td>
<td>32</td>
<td>51</td>
<td>54</td>
<td>47</td>
</tr>
<tr>
<td>Severe</td>
<td>0</td>
<td>35</td>
<td>20</td>
<td>0</td>
</tr>
</tbody>
</table>

**TABLE 2**

<table>
<thead>
<tr>
<th>Duration of treatment</th>
<th>No. of patients</th>
<th>OSD (%)</th>
<th>Schirmer (%)</th>
<th>T BUT (%)</th>
<th>Lissamine green (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>normal</td>
<td>mild-mod</td>
<td>severe</td>
<td>normal</td>
</tr>
<tr>
<td>˂1yr</td>
<td>10</td>
<td>100</td>
<td>0</td>
<td>0</td>
<td>60</td>
</tr>
<tr>
<td>1-5yr</td>
<td>36</td>
<td>78</td>
<td>22</td>
<td>0</td>
<td>59</td>
</tr>
<tr>
<td>5-10yr</td>
<td>19</td>
<td>65</td>
<td>35</td>
<td>0</td>
<td>40</td>
</tr>
<tr>
<td>˃10yr</td>
<td>10</td>
<td>44</td>
<td>66</td>
<td>0</td>
<td>20</td>
</tr>
</tbody>
</table>

**TABLE 3**

<table>
<thead>
<tr>
<th>No of drugs</th>
<th>No. of patients</th>
<th>OSD (%)</th>
<th>Schirmer (%)</th>
<th>T BUT (%)</th>
<th>Lissamine green (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>normal</td>
<td>Mild-mod</td>
<td>severe</td>
<td>normal</td>
</tr>
<tr>
<td>1</td>
<td>59</td>
<td>78</td>
<td>22</td>
<td>0</td>
<td>60</td>
</tr>
<tr>
<td>2</td>
<td>33</td>
<td>76</td>
<td>24</td>
<td>0</td>
<td>58</td>
</tr>
<tr>
<td>3</td>
<td>8</td>
<td>71</td>
<td>29</td>
<td>0</td>
<td>57</td>
</tr>
</tbody>
</table>
Graph 1

**TEST RESULTS**

- **Graph 2A**: OSD Score
  - Y-axis: % of Patients
  - X-axis: Duration of Therapy
  - Categories: <1 yr, 1-5 yr, 5-10 yr, >10 yr
  - Legend: severe, mild-mod, normal

- **Graph 2B**: Schirmer’s Test
  - Y-axis: % of Patients
  - X-axis: Duration of Therapy
  - Categories: <1yr, 1-5yr, 5-10yr, >10yr
  - Legend: severe, mild-mod, normal

- **Graph 2C**: BUT Test
  - Y-axis: % of Patients
  - X-axis: Duration of Therapy
  - Categories: <1 yr, 1-5 yr, 5-10 yr, >10 yr
  - Legend: severe, mild-mod, normal

- **Graph 2D**: LiSSaman Green Staining
  - Y-axis: % of Patients
  - X-axis: Duration of Therapy
  - Categories: <1 yr, 1-5 yr, 5-10 yr, >10 yr
  - Legend: severe, mild-mod, normal